![](https://investorshub.advfn.com/uicon/141223.png?cb=1598386268)
Wednesday, November 18, 2020 9:10:29 AM
https://www.biopharmadive.com/news/illumina-buy-grail-cancer-screening/585606/
Illumina has agreed to acquire Grail in an $8 billion deal that could establish the sequencing giant as a leading player in the growing race to use blood-based tests known as liquid biopsies to catch cancers early.
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM